RHYTHM PHARMACEUTICALS

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

05 May 2022 15:01:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present at BofA Securities 2022 Healthcare Conference

04 May 2022 07:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Update

03 May 2022 06:00:02 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome (BBS) at the Pediatric Endocrine Society (PES) 2022 Virtual Annual Meeting

02 May 2022 07:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022

26 Apr 2022 07:00:03 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

08 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity

06 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present at Cowen & Co. 42nd Annual Health Care Conference

01 Mar 2022 15:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

01 Mar 2022 06:00:03 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome

24 Feb 2022 07:00:02 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Promotions within its Executive Leadership Team

23 Feb 2022 07:00:02 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 1, 2022

22 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Positive Interim Data from Long-term Extension Study of Setmelanotide in Bardet-Biedl Syndrome (BBS)

16 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Host Virtual Bardet-Biedl Syndrome (BBS) Event on February 16

08 Feb 2022 15:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces First Patients Dosed in DAYBREAK and Weekly Trials Evaluating Setmelanotide for Rare Genetic Diseases of Obesity

13 Jan 2022 08:15:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals and RareStone Ltd. Announce Exclusive Licensing Agreement for the Development and Commercialization of IMCIVREE (setmelanotide) in China

06 Dec 2021 07:00:02 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome

15 Nov 2021 06:45:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present at Stifel 2021 Virtual Healthcare Conference

09 Nov 2021 15:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Third Quarter 2021 Financial Results

02 Nov 2021 06:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents First-ever Data Showing Improvements in Health-related Quality of Life for Patients Living with Bardet-Biedl Syndrome at ObesityWeek® 2021

01 Nov 2021 15:01:00 By Nasdaq GlobeNewswire